Gearing up for the launch of diabetes and heart failure drug Jardiance in chronic kidney disease, Boehringer Ingelheim has already started 2023 by posting strong pharma sales growth. | Boehringer reported an 11.3% jump in pharma sales during the first half of the year, largely thanks to Eli Lilly-partnered Jardiance. Now, the company is kicking off a chronic kidney disease launch for the medicine in Europe.
